Welcome to San Francisco Biotech Networks DAILY for 01/11/2026. Daily news and jobs are listed below. Please forward this email to your colleagues so they can subscribe at biotechnetworks.org/daily

​​​​​​​

Click a link below to view the mailing archive as if it had been sent to you.

2021-12-31 01:30Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing and more...
2021-12-30 01:3023andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
2021-12-29 01:30Year in Review: Bay Area fed its drug habit with FDA approvals and more...
2021-12-28 01:30Gilead Sciences sued over royalty payments on key HIV drug and more...
2021-12-27 01:30Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir and more...
2021-12-25 01:30Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer ...
2021-12-24 01:30A Peninsula biotech's FDA approval could shift the health prognosis for people of color and more...
2021-12-23 01:30New-year job cuts coming to Genentech as part of Roche product development shift and more...
2021-12-22 01:30ShouTi Appoints Ding Ding, Ph.D., as Chief Financial Officer and more...
2021-12-21 01:30Peninsula 'gene circuits' company taking blank-check route to go public and more...
2021-12-19 01:30Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome and more...
2021-12-18 01:30New smart-roof coating keeps homes warm in winter, cool in summer and more...
2021-12-17 01:30Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML and more...
2021-12-16 01:30The Ritz-Carlton Collaborates with BioGreen360 and Garick to Develop a 100% Circular Solution for Food Waste and more...
2021-12-15 01:30Geron Reports Presentations at American Society of Hematology Annual Meeting and more...
2021-12-14 01:30Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition and more...
2021-12-13 01:30Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting and more...
2021-12-12 01:30Op-ed: What we’re watching closely as an unusual #ASH21 kicks off in Atlanta and more...
2021-12-11 01:30Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and more...
2021-12-10 01:30Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management ...
2021-12-09 01:30Talis Biomedical Announces Leadership Transition and more...
2021-12-08 01:30Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock and more...
2021-12-07 01:30Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021 and more...
2021-12-04 01:30dMY Technology Group, Inc. IV Stockholders Approve Proposed Business Combination with Planet and more...
2021-12-03 01:30Berkeley Lights Debuts in France as MImAbs Acquires the Beacon® Optofluidic System for Antibody Discovery and more...
2021-12-02 01:30Former Genmark Senior Vice President Scott O'Brien Joins Specific Diagnostics as Chief Commercial Officer and more...
2021-12-01 01:30Chloro-phylling in the Answers to Big Questions and more...

 

<< Archive Index • Subscribe >>

 

© Biotech Networks. You're receiving this email because you've signed up to receive updates from us.

If you'd prefer not to receive updates, you can unsubscribe.
 
© FeedBlitz® - Win the Inbox ™ | feedblitz.com | info@feedblitz.com | Privacy | Terms of Service
 English | Português | Français | Español | Italiano | Nederlands | Svenska | Deutsch | 日本語